Urinary levels of tumor-associated trypsin inhibitor (TATI) in the detection of transitional cell carcinoma of the urinary bladder.

[1]  A. Sagalowsky,et al.  Risk stratification for bladder tumor recurrence, stage and grade by urinary nuclear matrix protein 22 and cytology. , 2004, European urology.

[2]  T. Gasser,et al.  Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. , 2004, The Journal of urology.

[3]  M. Ferdeghini,et al.  Assessment of tumor-associated trypsin inhibitor (TATI) as a marker of renal function. , 2003, Journal of nephrology.

[4]  J. Southgate,et al.  Identification of genes up-regulated in urothelial tumors: the 67-kd laminin receptor and tumor-associated trypsin inhibitor. , 2003, The American journal of pathology.

[5]  U. Stenman,et al.  Tumor-associated trypsin inhibitor as a prognostic factor during follow-up of bladder cancer. , 2003, Urology.

[6]  C. Roehrborn,et al.  Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. , 2003, Urology.

[7]  U. Stenman.  Tumor-associated trypsin inhibitor. , 2002, Clinical chemistry.

[8]  T. Salo,et al.  The levels of trypsinogen isoenzymes in ovarian tumour cyst fluids are associated with promatrix metalloproteinase-9 but not promatrix metalloproteinase-2 activation , 2001, British Journal of Cancer.

[9]  U. Stenman,et al.  Pre‐operative serum level of tumour‐associated trypsin inhibitor and residual turnour size as prognostic indicators in Stage III epithelial ovarian cancer , 1998, British journal of obstetrics and gynaecology.

[10]  D. Pectasides,et al.  TPA, TATI, CEA, AFP, beta-HCG, PSA, SCC, and CA 19-9 for monitoring transitional cell carcinoma of the bladder. , 1996, American journal of clinical oncology.

[11]  O. Cussenot,et al.  Tumour-associated trypsin inhibitor and renal cell carcinoma. , 1995, European urology.

[12]  U. Stenman,et al.  Tumour-associated trypsin inhibitor (TATI): comparison with CA125 as a preoperative prognostic indicator in advanced ovarian cancer. , 1994, British Journal of Cancer.

[13]  O. Itkonen,et al.  Optimization of a time-resolved immunofluorometric assay for tumor-associated trypsin inhibitor (TATI) using the streptavidin-biotin system. , 1993, Journal of immunological methods.

[14]  G. Vooijs,et al.  Accuracy of urinary cytology in the diagnosis of primary and recurrent bladder cancer. , 1993, Acta cytologica.

[15]  W. Taccone,et al.  Evaluation of TATI and other markers in solid tumors. , 1991, Scandinavian journal of clinical and laboratory investigation. Supplementum.

[16]  O. Itkonen,et al.  Biology and function of tumor-associated trypsin inhibitor, TATI. , 1991, Scandinavian journal of clinical and laboratory investigation. Supplementum.

[17]  E. DeLong,et al.  Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.

[18]  S. Nordling,et al.  Tumour-associated trypsin inhibitor, TATI, in patients with pancreatic cancer, pancreatitis and benign biliary diseases. , 1986, British Journal of Cancer.

[19]  M. Fukayama,et al.  Immunohistochemical localization of pancreatic secretory trypsin inhibitor in fetal and adult pancreatic and extrapancreatic tissues. , 1986, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[20]  U. Stenman,et al.  Immunochemical demonstration of an ovarian cancer‐associated urinary peptide , 1982, International journal of cancer.